{
  "metadata": {
    "case_id": 98,
    "model": "Claude-4.5-Sonnet",
    "timestamp": "2025-11-29T19:55:12.010646",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/98_NCT02910583.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Claude-4.5-Sonnet/98_Claude-4.5-Sonnet.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 5,
      "pred_count": 5,
      "similarity_matrix": [
        [
          0.97,
          0.18,
          0.62,
          0.4,
          0.88
        ],
        [
          0.82,
          0.4,
          0.82,
          0.78,
          0.72
        ],
        [
          0.65,
          0.82,
          0.82,
          0.55,
          0.72
        ],
        [
          0.86,
          0.3,
          0.78,
          0.86,
          0.7
        ],
        [
          0.86,
          0.15,
          0.7,
          0.8,
          0.96
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "label": "Fixed Duration (FD) Cohort: Open Label Ibrutinib + Venetoclax",
            "type": "EXPERIMENTAL",
            "description": "Participants receive 420 mg of single-agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment (ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule) for 12 cycles (a cycle is defined by 28 days) or until disease progression or unacceptable toxicity.",
            "interventionNames": [
              "Drug: ibrutinib",
              "Drug: venetoclax"
            ]
          },
          "pred_item": {
            "label": "Ibrutinib Lead-in (Prerandomization Phase)",
            "type": "EXPERIMENTAL",
            "description": "All patients received 3 cycles of single-agent oral ibrutinib (420 mg once daily) lead-in, followed by 12 cycles of ibrutinib plus oral venetoclax (target dose 400 mg once daily after standard 5-week ramp-up). Each cycle was 28 days.",
            "interventionNames": [
              "DRUG: Ibrutinib",
              "DRUG: Venetoclax"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.82,
          "status": "matched",
          "ref_item": {
            "label": "MRD Cohort/Confirmed Undetectable MRD (uMRD): Randomized to Ibrutinib (Blinded)",
            "type": "EXPERIMENTAL",
            "description": "Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase).\n\nParticipants with confirmed uMRD are randomized to receive ibrutinib 420 mg orally once daily on a continuous schedule until MRD-positive relapse, disease progression (PD), or unacceptable toxicity.\n\nAfter MRD-positive relapse or disease progression (PD) by iwCLL criteria, participants can reintroduce 400 mg venetoclax with a 5-week ramp up. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity.",
            "interventionNames": [
              "Drug: ibrutinib",
              "Drug: venetoclax"
            ]
          },
          "pred_item": {
            "label": "Confirmed uMRD: Ibrutinib (Randomization Phase)",
            "type": "EXPERIMENTAL",
            "description": "Patients with Confirmed undetectable MRD (uMRD) were randomly assigned 1:1 to receive double-blinded ibrutinib until confirmed MRD relapse or disease progression.",
            "interventionNames": [
              "DRUG: Ibrutinib"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 1,
          "score": 0.82,
          "status": "matched",
          "ref_item": {
            "label": "MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded)",
            "type": "PLACEBO_COMPARATOR",
            "description": "Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase).\n\nParticipants with confirmed uMRD are randomized to receive placebo orally once daily on a continuous schedule until MRD-positive relapse, PD or unacceptable toxicity.\n\nIf MRD-positive relapse or PD is confirmed after restaging per iwCLL criteria, participants can first reintroduce oral daily ibrutinib with the option of subsequently reintroducing 400 mg venetoclax with a 5-week ramp up, if subsequent disease relapse per iwCLL criteria occurs after ibrutinib reintroduction. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity.",
            "interventionNames": [
              "Drug: ibrutinib",
              "Drug: venetoclax",
              "Drug: Placebo"
            ]
          },
          "pred_item": {
            "label": "Confirmed uMRD: Placebo (Randomization Phase)",
            "type": "PLACEBO_COMPARATOR",
            "description": "Patients with Confirmed undetectable MRD (uMRD) were randomly assigned 1:1 to receive double-blinded placebo until confirmed MRD relapse or disease progression.",
            "interventionNames": [
              "DRUG: Placebo"
            ]
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 3,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "label": "MRD Cohort/uMRD Not Confirmed: Randomized to Ibrutinib (Open-Label)",
            "type": "EXPERIMENTAL",
            "description": "Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase).\n\nParticipants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg orally once daily on a continuous schedule until PD or unacceptable toxicity.\n\nIn case of confirmed PD after restaging per iwCLL criteria, participants can continue ibrutinib and reintroduce venetoclax treatment. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity.",
            "interventionNames": [
              "Drug: ibrutinib",
              "Drug: venetoclax"
            ]
          },
          "pred_item": {
            "label": "uMRD Not Confirmed: Ibrutinib (Randomization Phase)",
            "type": "EXPERIMENTAL",
            "description": "Patients who did not meet strict Confirmed uMRD criteria (uMRD Not Confirmed) were randomly assigned 1:1 to receive open-label single-agent ibrutinib until disease progression or unacceptable toxicity.",
            "interventionNames": [
              "DRUG: Ibrutinib"
            ]
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": 4,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "MRD Cohort/uMRD Not Confirmed: Randomized Ibrutinib + Venetoclax (Open-Label)",
            "type": "EXPERIMENTAL",
            "description": "Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase).\n\nParticipants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule until PD or unacceptable toxicity. Venetoclax was allowed for administration up to 2 years cumulatively from first dose started in the pre-randomization phase to last dose in the randomization phase.",
            "interventionNames": [
              "Drug: ibrutinib",
              "Drug: venetoclax"
            ]
          },
          "pred_item": {
            "label": "uMRD Not Confirmed: Ibrutinib plus Venetoclax (Randomization Phase)",
            "type": "EXPERIMENTAL",
            "description": "Patients who did not meet strict Confirmed uMRD criteria (uMRD Not Confirmed) were randomly assigned 1:1 to receive open-label ibrutinib plus venetoclax (maximum 2 years overall duration for venetoclax) until disease progression or unacceptable toxicity.",
            "interventionNames": [
              "DRUG: Ibrutinib",
              "DRUG: Venetoclax"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.92,
          0.3,
          0.4
        ],
        [
          0.4,
          0.96,
          0.2
        ],
        [
          0.3,
          0.1,
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "ibrutinib",
            "description": "ibrutinib administered orally once daily (three 140 mg capsules)",
            "armGroupLabels": [
              "Fixed Duration (FD) Cohort: Open Label Ibrutinib + Venetoclax",
              "MRD Cohort/Confirmed Undetectable MRD (uMRD): Randomized to Ibrutinib (Blinded)",
              "MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded)",
              "MRD Cohort/uMRD Not Confirmed: Randomized Ibrutinib + Venetoclax (Open-Label)",
              "MRD Cohort/uMRD Not Confirmed: Randomized to Ibrutinib (Open-Label)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Ibrutinib",
            "description": "Oral Bruton tyrosine kinase (BTK) inhibitor administered at 420 mg once daily",
            "armGroupLabels": [
              "Ibrutinib Lead-in (Prerandomization Phase)",
              "Confirmed uMRD: Ibrutinib (Randomization Phase)",
              "uMRD Not Confirmed: Ibrutinib (Randomization Phase)",
              "uMRD Not Confirmed: Ibrutinib plus Venetoclax (Randomization Phase)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "venetoclax",
            "description": "venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.",
            "armGroupLabels": [
              "Fixed Duration (FD) Cohort: Open Label Ibrutinib + Venetoclax",
              "MRD Cohort/Confirmed Undetectable MRD (uMRD): Randomized to Ibrutinib (Blinded)",
              "MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded)",
              "MRD Cohort/uMRD Not Confirmed: Randomized Ibrutinib + Venetoclax (Open-Label)",
              "MRD Cohort/uMRD Not Confirmed: Randomized to Ibrutinib (Open-Label)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Venetoclax",
            "description": "Oral B-cell lymphoma 2 (BCL-2) inhibitor administered at target dose 400 mg once daily after standard 5-week ramp-up, with tumor lysis syndrome (TLS) prophylaxis and monitoring",
            "armGroupLabels": [
              "Ibrutinib Lead-in (Prerandomization Phase)",
              "uMRD Not Confirmed: Ibrutinib plus Venetoclax (Randomization Phase)"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 2,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "placebo capsules to match ibrutinib administered orally once daily",
            "armGroupLabels": [
              "MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Double-blinded placebo administered to patients with Confirmed uMRD",
            "armGroupLabels": [
              "Confirmed uMRD: Placebo (Randomization Phase)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.98
        ],
        [
          0.1
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants",
            "description": "DFS is defined as time from randomization date to MRD-positive relapse, or disease progression per investigator assessment (per 2008 International Workshop for Chronic Lymphocytic Leukemia \\[IWCLL\\] criteria \\[Halleck et al\\]) or death from any cause, whichever occurred first. 1-year DFS estimated using Kaplan-Meier method at 12 months landmark time.",
            "timeFrame": "1 year after randomization"
          },
          "pred_item": {
            "measure": "1-year Disease-Free Survival (DFS) Rate in Confirmed uMRD Population",
            "description": "1-year DFS was defined as absence of MRD relapse, progression, or death at least 1 year after random assignment. DFS was evaluated in patients with Confirmed undetectable minimal residual disease (uMRD) randomly assigned to placebo versus ibrutinib.",
            "timeFrame": "1 year after random assignment"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "FD Cohort: Complete Response Rate (CRR; Complete Response/Complete Response With Incomplete Blood Count Recovery [CR/CRi]) Rate",
            "description": "CR/CRi rate is defined as the percentage of participants achieving a best overall response of complete response (CR), CR with incomplete blood count recovery (CRi) per 2008 IWCLL criteria (halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier.",
            "timeFrame": "From the first dose of ibrutinib to the first confirmed PD, for a median follow-up of 69.0 months."
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 24,
      "pred_count": 10,
      "similarity_matrix": [
        [
          0.38,
          0.35,
          0.83,
          0.92,
          0.18,
          0.08,
          0.18,
          0.18,
          0.08,
          0.08
        ],
        [
          0.35,
          0.35,
          0.86,
          0.62,
          0.35,
          0.18,
          0.22,
          0.18,
          0.1,
          0.08
        ],
        [
          0.32,
          0.32,
          0.55,
          0.4,
          0.96,
          0.08,
          0.62,
          0.28,
          0.05,
          0.08
        ],
        [
          0.92,
          0.94,
          0.4,
          0.4,
          0.1,
          0.12,
          0.1,
          0.08,
          0.05,
          0.05
        ],
        [
          0.18,
          0.25,
          0.1,
          0.08,
          0.02,
          0.98,
          0.08,
          0.03,
          0.25,
          0.18
        ],
        [
          0.32,
          0.32,
          0.28,
          0.18,
          0.38,
          0.12,
          0.88,
          0.35,
          0.05,
          0.08
        ],
        [
          0.32,
          0.2,
          0.12,
          0.18,
          0.2,
          0.09,
          0.6,
          0.9,
          0.12,
          0.08
        ],
        [
          0.18,
          0.18,
          0.08,
          0.12,
          0.02,
          0.08,
          0.08,
          0.05,
          0.05,
          0.9
        ],
        [
          0.2,
          0.25,
          0.9,
          0.52,
          0.42,
          0.18,
          0.22,
          0.05,
          0.08,
          0.08
        ],
        [
          0.2,
          0.22,
          0.55,
          0.55,
          0.9,
          0.08,
          0.45,
          0.32,
          0.05,
          0.05
        ],
        [
          0.9,
          0.86,
          0.4,
          0.42,
          0.08,
          0.12,
          0.08,
          0.05,
          0.05,
          0.08
        ],
        [
          0.12,
          0.2,
          0.18,
          0.15,
          0.4,
          0.12,
          0.95,
          0.4,
          0.15,
          0.08
        ],
        [
          0.05,
          0.08,
          0.12,
          0.18,
          0.1,
          0.05,
          0.6,
          0.72,
          0.03,
          0.08
        ],
        [
          0.08,
          0.08,
          0.12,
          0.18,
          0.07,
          0.97,
          0.08,
          0.05,
          0.18,
          0.18
        ],
        [
          0.1,
          0.1,
          0.2,
          0.1,
          0.08,
          0.1,
          0.1,
          0.08,
          0.05,
          0.93
        ],
        [
          0.2,
          0.15,
          0.08,
          0.07,
          0.05,
          0.08,
          0.03,
          0.05,
          0.82,
          0.12
        ],
        [
          0.18,
          0.2,
          0.08,
          0.05,
          0.05,
          0.08,
          0.05,
          0.02,
          0.82,
          0.08
        ],
        [
          0.12,
          0.18,
          0.08,
          0.05,
          0.02,
          0.18,
          0.1,
          0.05,
          0.82,
          0.05
        ],
        [
          0.08,
          0.12,
          0.05,
          0.02,
          0.03,
          0.09,
          0.02,
          0.0,
          0.78,
          0.1
        ],
        [
          0.1,
          0.08,
          0.07,
          0.05,
          0.03,
          0.12,
          0.04,
          0.02,
          0.8,
          0.1
        ],
        [
          0.18,
          0.18,
          0.1,
          0.08,
          0.07,
          0.1,
          0.05,
          0.05,
          0.72,
          0.12
        ],
        [
          0.18,
          0.18,
          0.05,
          0.07,
          0.03,
          0.15,
          0.05,
          0.05,
          0.78,
          0.05
        ],
        [
          0.22,
          0.22,
          0.05,
          0.1,
          0.05,
          0.12,
          0.05,
          0.08,
          0.86,
          0.12
        ],
        [
          0.21,
          0.18,
          0.05,
          0.05,
          0.1,
          0.12,
          0.05,
          0.05,
          0.76,
          0.08
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 3,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: CRR (CR/CRi Rate)",
            "description": "CR/CRi rate is defined as the percentage of participants achieving a best overall response of CR or CRi per 2008 IWCLL criteria (Halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier.\n\nMedian follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.",
            "timeFrame": "From the first dose of ibrutinib to the first confirmed PD, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)"
          },
          "pred_item": {
            "measure": "Complete Response (CR) Rate",
            "description": "Proportion of patients achieving CR or CR with incomplete bone marrow recovery (CRi) per 2008 iwCLL criteria.",
            "timeFrame": "Best response during prerandomization phase (approximately 15 months) and postrandomization phase (up to approximately 31.3 months median follow-up)"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: Overall Response Rate (ORR)",
            "description": "ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), partial response (PR), or PR with lymphocytosis (PRL) evaluated in accordance with the 2008 IWCLL criteria (Halleck et al). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate.\n\nMedian follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.",
            "timeFrame": "From the first dose of ibrutinib to the first confirmed PD, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": 4,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: Duration of Response (DOR) at 42 Months Landmark Time",
            "description": "Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of 67.0 months study follow-up, the Kaplan-Meier estimate of DOR at 42 months landmark time was presented.\n\nMedian follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.",
            "timeFrame": "From initial documentation of a response until PD or death from any cause, whichever occurs first, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)"
          },
          "pred_item": {
            "measure": "Duration of Response",
            "description": "Time from first documentation of response (CR, CRi, PR, or nodular PR) to disease progression or death.",
            "timeFrame": "From time of response to progression or death, assessed up to approximately 31.3 months median follow-up"
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 1,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: MRD-Negativity Rate",
            "description": "MRD negativity rate is defined as the percentage of participants achieving MRD negativity, which is defined as \\<1 CLL cell per 10,000 leukocytes (\\<1 x 10\\^-4) as assessed by flow cytometry of a peripheral blood (PB) or bone marrow (BM) aspirate sample per central laboratory on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier.\n\nMedian follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.",
            "timeFrame": "From randomization date until before any subsequent antineoplastic therapy, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)"
          },
          "pred_item": {
            "measure": "Undetectable Minimal Residual Disease (uMRD) Rates in Bone Marrow",
            "description": "Proportion of patients achieving uMRD (defined as < 1 CLL cell per 10,000 leukocytes) in bone marrow assessed by flow cytometry.",
            "timeFrame": "After completion of 12 cycles of ibrutinib plus venetoclax (approximately cycle 16)"
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": 5,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: Tumor Lysis Syndrome (TLS) Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)",
            "description": "TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) \\< 5 cm AND absolute lymphocyte count (ALC) \\< 25 x 10\\^9/L; Medium=Any LN 5 cm to \\< 10 cm OR ALC ≥ 25 x 10\\^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10\\^9/L AND any LN ≥ 5 cm.",
            "timeFrame": "Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib)."
          },
          "pred_item": {
            "measure": "Tumor Lysis Syndrome (TLS) Risk Category Reduction",
            "description": "Proportion of patients at high risk for TLS at baseline who shifted to medium or low TLS risk categories after ibrutinib lead-in.",
            "timeFrame": "At baseline and after 3 cycles of ibrutinib lead-in (approximately 3 months)"
          }
        },
        {
          "ref_idx": 5,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: Kaplan-Meier Estimate of Progression Free Survival (PFS) Rate at 48 Months Landmark Time",
            "description": "PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the overall median 67.0 months study follow-up, the Kaplan-Meier estimate of PFS rate at 48 months landmark time was presented.\n\nMedian follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.",
            "timeFrame": "From the first dose of ibrutinib to the first confirmed PD or death, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 6,
          "pred_idx": 7,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: Kaplan-Meier Estimate of Overall Survival (OS) Rate at 48 Months Landmark Time",
            "description": "OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the overall median 67.0 months study follow-up, the Kaplan-Meier estimate of OS rate at 48 months landmark time was presented.\n\nMedian follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD: Randomized to Ibrutinib=69.1 months; Confirmed uMRD: Randomized to Placebo=67.4 months; uMRD Not Confirmed: Randomized to Open-Label Ibrutinib=47.9 months; uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax=47.9 months.",
            "timeFrame": "From the first dose of ibrutinib to time of death, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)"
          },
          "pred_item": {
            "measure": "Overall Survival (OS)",
            "description": "Time from first dose of study treatment to death from any cause.",
            "timeFrame": "Up to approximately 31.3 months median follow-up"
          }
        },
        {
          "ref_idx": 7,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Discontinuations Due to TEAEs",
            "description": "An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization \\>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug.",
            "timeFrame": "From first dose until 30 days following last dose of study drug. Overall median treatment duration for the MRD cohort was 45.1 months."
          },
          "pred_item": null
        },
        {
          "ref_idx": 8,
          "pred_idx": 2,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "FD Cohort: ORR",
            "description": "ORR is defined as the percentage of participants who achieve a best overall response CR, CRi, nPR, PR, or PRL as evaluated by investigator using 2008 IWCLL criteria (Halleck et al.). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate.",
            "timeFrame": "From the first dose of ibrutinib to the first confirmed PD, for a median follow-up of 69.0 months."
          },
          "pred_item": {
            "measure": "Overall Response Rate",
            "description": "Proportion of patients achieving complete response (CR), CR with incomplete bone marrow recovery (CRi), partial response (PR), or nodular PR per investigator assessment using 2008 iwCLL criteria.",
            "timeFrame": "Best response during prerandomization phase (approximately 15 months) and postrandomization phase (up to approximately 31.3 months median follow-up)"
          }
        },
        {
          "ref_idx": 9,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "FD Cohort: DOR at 60 Months Landmark Time",
            "description": "Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of the median 27.9 months study follow-up, the Kaplan-Meier estimate of DOR at 60 months landmark time was presented.",
            "timeFrame": "From initial documentation of a response until PD or death from any cause, whichever occurs first, for a median follow-up of 69.0 months."
          },
          "pred_item": null
        },
        {
          "ref_idx": 10,
          "pred_idx": 0,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "FD Cohort: MRD Negativity Rate",
            "description": "MRD negativity rate is defined as the percentage of participants achieving MRD negativity, which is defined as \\<1 CLL cell per 10,000 leukocytes (\\<1 x 10\\^-4) as assessed by flow cytometry of a peripheral blood (PB) or bone marrow (BM) aspirate sample per central laboratory on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier.",
            "timeFrame": "From randomization date until before any subsequent antineoplastic therapy, for a median follow-up of 69.0 months."
          },
          "pred_item": {
            "measure": "Undetectable Minimal Residual Disease (uMRD) Rates in Peripheral Blood",
            "description": "Proportion of patients achieving uMRD (defined as < 1 CLL cell per 10,000 leukocytes) in peripheral blood assessed by flow cytometry.",
            "timeFrame": "During and after 12 cycles of ibrutinib plus venetoclax (approximately 15 months from treatment initiation)"
          }
        },
        {
          "ref_idx": 11,
          "pred_idx": 6,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "measure": "FD Cohort: Kaplan-Meier Estimate of PFS Rate at 66 Months Landmark Time",
            "description": "PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the median 69.0 months study follow-up, the Kaplan-Meier estimate of PFS rate at 66 months landmark time was presented.",
            "timeFrame": "From the first dose of ibrutinib to the first confirmed PD or death, for an median follow-up of 69.0 months."
          },
          "pred_item": {
            "measure": "Progression-Free Survival (PFS)",
            "description": "Time from first dose of study treatment to disease progression or death from any cause.",
            "timeFrame": "Up to approximately 31.3 months median follow-up"
          }
        },
        {
          "ref_idx": 12,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "FD Cohort: Kaplan-Meier Estimate of OS Rate at 66 Months Landmark Time",
            "description": "OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the median 69.0 months study follow-up, the Kaplan-Meier estimate of OS rate at 66 months landmark time was presented.",
            "timeFrame": "From the first dose of ibrutinib to time of death, for a median follow-up of 69.0 months."
          },
          "pred_item": null
        },
        {
          "ref_idx": 13,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "FD Cohort: TLS Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)",
            "description": "TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) \\< 5 cm AND absolute lymphocyte count (ALC) \\< 25 x 10\\^9/L; Medium=Any LN 5 cm to \\< 10 cm OR ALC ≥ 25 x 10\\^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10\\^9/L AND any LN ≥ 5 cm.",
            "timeFrame": "Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib)."
          },
          "pred_item": null
        },
        {
          "ref_idx": 14,
          "pred_idx": 9,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "measure": "FD Cohort: Percentage of Participants With TEAEs, Treatment-Emergent SAEs, and Discontinuations Due to TEAEs",
            "description": "An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization \\>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug.",
            "timeFrame": "From first dose until 30 days following last dose of study drug. Overall median treatment duration for the FD cohort was 13.8 months."
          },
          "pred_item": {
            "measure": "Safety and Tolerability",
            "description": "Frequency and severity of adverse events (AEs), serious AEs, treatment-emergent AEs, AEs leading to dose modifications or discontinuations, and deaths.",
            "timeFrame": "Throughout treatment period and follow-up, up to approximately 31.3 months median follow-up"
          }
        },
        {
          "ref_idx": 15,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: Pharmacokinetics (PK) of Ibrutinib When Dosed in Combination With Venetoclax: Observed Maximum Concentration (Cmax)",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 16,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Time to Cmax (Tmax); Time of Last Measurable Concentration (Tlast); Terminal Elimination Half-Life (t1/2,Term)",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 17,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Area Under the Plasma Concentration-Time Curve (AUC) Over the Last 24-hour Dosing Interval (AUC0-24h); AUC From Time Zero to the Time of Last Quantifiable Concentration (AUClast)",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 18,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Terminal Elimination Rate Constant (λz)",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 19,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Apparent Total Clearance at Steady-State (CLss/F)",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 20,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Cmax",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 21,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Tmax",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 22,
          "pred_idx": 8,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: AUC0-24h",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": {
            "measure": "Pharmacokinetics of Ibrutinib and Venetoclax in Combination",
            "description": "Plasma area under the curve (AUC) of ibrutinib when coadministered with venetoclax versus single-agent ibrutinib, and venetoclax AUC when coadministered with ibrutinib.",
            "timeFrame": "During single-agent ibrutinib lead-in and during combination treatment (approximately first 4 months of treatment)"
          }
        },
        {
          "ref_idx": 23,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: CLss/F",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        }
      ]
    }
  ]
}